LB Pharmaceuticals LB-102-010
About the Study
This study is for adults with schizophrenia who are currently stable, but are experiencing either an inadequate response to their current antipsychotic medication and desire to change medications, or experiencing issues with side effects, general tolerability, or overall effectiveness of their current antipsychotic medication and desire to change medications.
The purpose of this study is to evaluate the long-term safety and tolerability of LB-102 with doses from 50mg to 100mg administered once daily in adults with schizophrenia. All qualified participants will receive LB-102 100mg QD. The dose of LB-102 will be evaluated at each following study visit and adjusted if needed, ranging from 50mg to 100mg.
This study is sponsored by LB Pharmaceuticals.
Eligibility
You may be eligible to participate in this study if you:
are 18-65 years of age
have a primary diagnosis of schizophrenia based on DSM-5 criteria, and confirmed by the MINI assessment
are willing and able discontinue to commit to a year long study
are prescribed and taking a therapeutic dose of an oral antipsychotic medication for at least 30 days prior to screening, EXCEPT for the following medications: Abilify/aripiprazole, Rexulti/brexpiprazole, or Vraylar/cariprazine.
If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.
If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.